Daily Medication Pearl: Anifrolumab-fnia (Saphnelo)

Author(s):

Saro Arakelians, PharmD

Key Takeaways

Anifrolumab-fnia is indicated for moderate to severe systemic lupus erythematosus in adults receiving standard therapy.
Administered as a 300 mg intravenous infusion every four weeks, it comes in a single-dose vial.
Common adverse reactions include nasopharyngitis, upper respiratory infections, and infusion-related reactions.
The drug inhibits type I IFN signaling by binding to the receptor's subunit 1 with high specificity and affinity.

Anifrolumab-fnia is a human immunoglobulin G (IgG)1κ monoclonal antibody indicated for the treatment of moderate to severe systemic lupus erythematosus.

Medication Pearl of the Day: Anifrolumab-fnia (Saphnelo)

Indication: Saphnelo is a type I interferon (IFN) receptor antagonist indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus, who are receiving standard therapy.

Insight:

Dosing: The recommended dosage is 300 mg as an intravenous infusion over a 30-minute period every 4 weeks.
Dosage forms: Injection 300 mg/2 mL (150 mg/mL) in a single-dose vial.
Adverse events: Most common adverse drug reactions (incidence ≥5%) are nasopharyngitis, upper respiratory tract infections, bronchitis, infusion-related reactions, herpes zoster, and cough.
Mechanism of action: Anifrolumab-fnia is a human immunoglobulin G (IgG)1κ monoclonal antibody that binds to subunit 1 of the type I interferon receptor with high specificity and affinity. This binding inhibits type I IFN signaling, thereby blocking the biologic activity of type I IFNs.
Manufacturer: AstraZeneca

Sources:

https://www.azpicentral.com/pi.html?product=saphnelo

saphnelo image - Google Search

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!